HIV Infections Clinical Trial
Official title:
Cognitive and Psychosocial Benefits of Caregiver Training for Ugandan HIV Children
The Mediational Interventions for Sensitizing Caregivers (MISC) model developed by Professor Pnina Klein is to enhance the cognitive and social development of children throughout the developing world . Although MISC has proven effective in a longitudinal study in two poorer communities of Addis Ababa, Ethiopia , it has not been used with HIV households or in the Ugandan context where there is desperate need for enhanced caregiving in HIV-affected families. We propose to work with community leaders, healthcare workers, and parents/caregivers in adapting MISC to the Ugandan cultural and social context in Kayunga. For intervention families, MISC training will be added to an ongoing home health care visit (HHCV) program already in place for HIV children in Kayunga district. We will then evaluate whether MISC parent/caregiver training improves cognitive and psychosocial development in their children, and whether clinical stability of the HIV child is an important modifier for MISC training benefit.
In Uganda, about 110,000 children 0 to 14 years are living with AIDS however enhanced access
to ARV medications has changed the prognosis for infected children from a uniformly deadly
disease early in childhood to one in which survival well into adolescence is not uncommon.
However, these prognostic changes have made psychosocial, educational, and quality-of-life
considerations for the HIV child all the more critical. Studies on Ugandan HIV infected
children show that they have cognitive, motor and emotional problems. These findings support
the need for caregiving interventions with HIV children that extend beyond provision for
basic medical and nutritional care only. These findings support the urgent need for programs
that minister to the emotional and psychosocial needs of HIV-affected children.
The MISC is one such intervention that has proven effective in improving the cognitive,
psychosocial and emotional needs of disadvantaged children. The MISC intervention is based
on the use of naturally occurring situations and objects in the home environment. The
process of training the caregivers in MISC theory and strategies is structured, whereas the
process of implementing MISC with the children in the household is individualized and
unstructured. The training of the caregiver is focused on the acquisition of knowledge and
skills necessary for effective intervention to enrich the child's home-based learning
environment.
Specific Objectives.
1. To establish the feasibility of MISC for caregivers of HIV infected children in
Kayunga.
2. To investigate whether cognition and psychosocial functioning of HIV infected children
are improved by MISC.
3. To determine whether cognitive and psychosocial gains for children of MISC-trained
caregivers is moderated by disease severity of the child.
3. METHODS Phase 1: Adaptation of the MISC Study design. Adaptation of the MISC will be done
using a cross sectional descriptive study. Prior to recruitment of participants, Prof. Klein
will hold a series of focus group discussions (FDGs) in Kayunga to critique the MISC
intervention.
Study population. Community leaders, health workers and parents/caregivers in Kayunga
district, three FGDs will be held for each of these groups. They will partner with Dr. Klein
in revising and adapting the MISC curriculum for training the local MISC staff who will
accompany the CAI teams as they visit the HIV children and caregivers for the home health
care visitation (HHCV). These CAI nursing staff will then train the caregivers each month as
part of these HHCV visits.
Phase 2: MISC intervention Study design. This will be a randomized control study where HIV
infected children younger than 6 yrs of age will be recruited and randomly assigned to
either MISC intervention or non- intervention. All children will be recruited from the Child
Health Advocacy International (CAI) project in Kayunga district during their routine home
visits. Consecutive sampling will be used till the sample size is reached.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |